| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | alisertib | CTRPv2 | pan-cancer | AAC | 0.053 | 0.1 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | 0.059 | 0.1 |
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | -0.092 | 0.1 |
| mRNA | PHA-665752 | GDSC1000 | pan-cancer | AAC | -0.089 | 0.1 |
| mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.056 | 0.1 |
| mRNA | TPCA-1 | CTRPv2 | pan-cancer | AAC | 0.053 | 0.1 |
| mRNA | BRD1812 | CTRPv2 | pan-cancer | AAC | 0.058 | 0.1 |
| mRNA | PL-DI | CTRPv2 | pan-cancer | AAC | 0.052 | 0.1 |
| mRNA | NSC 74859 | CTRPv2 | pan-cancer | AAC | 0.063 | 0.1 |
| mRNA | LFM-A13 | GDSC1000 | pan-cancer | AAC | -0.057 | 0.1 |